• Explore /
  • Poster
  • / MAIN-CAV: Phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy in patients with metastatic urothelial cancer (mUC) (Alliance A032001).

MAIN-CAV: Phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy in patients with metastatic urothelial cancer (mUC) (Alliance A032001).

Abstract Poster

Authors

Shilpa Gupta

Shilpa Gupta

Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

Shilpa Gupta , Karla V. Ballman , Matt D. Galsky , Michael J. Morris , Ronald C. Chen , Timothy A. Chan , Laurent Dercle , Yujia Wen , Srikala S. Sridhar , Aihua Edward Yen , Petros Grivas , Alan Tan , Shiva Baghaie , Jonathan E. Rosenberg

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Urothelial Cancer - Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT05092958

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS4607)

DOI

10.1200/JCO.2022.40.16_suppl.TPS4607

Abstract #

TPS4607

Poster Bd #

93b

Abstract Disclosures

Similar Posters

First Author: Shilpa Gupta

First Author: Shilpa Gupta

First Author: Shoma Yamamoto

First Author: Inkeun Park